Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens
Authors
Keywords
-
Journal
Pharmacogenetics and Genomics
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-11-01
DOI
10.1097/fpc.0000000000000515
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials
- (2021) Kristine M Erlandson et al. CLINICAL INFECTIOUS DISEASES
- Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy
- (2020) Jordan E Lake et al. CLINICAL INFECTIOUS DISEASES
- CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
- (2020) Rulan Griesel et al. CLINICAL INFECTIOUS DISEASES
- Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens
- (2020) Michael A Leonard et al. CLINICAL INFECTIOUS DISEASES
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for CYP 2B6 and Efavirenz‐containing Antiretroviral Therapy
- (2019) Zeruesenay Desta et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
- (2018) David V Glidden et al. CLINICAL INFECTIOUS DISEASES
- A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
- (2018) Mario Gomez et al. INFECTION
- Objective and Subjective Improvement of Cognition After Discontinuing Efavirenz in Asymptomatic Patients
- (2018) C.S. Hakkers et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects
- (2017) Nadezda Apostolova et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Brief Report
- (2017) Jamison Norwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants
- (2017) Katie R Mollan et al. JOURNAL OF INFECTIOUS DISEASES
- Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy
- (2017) Kristine M. Erlandson et al. JOURNAL OF INFECTIOUS DISEASES
- Long-term body composition changes in antiretroviral-treated HIV-infected individuals
- (2016) Philip M. Grant et al. AIDS
- Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation inCYP2B6*6*6Allele Carriers
- (2016) AHMED M. ABDELHADY et al. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
- Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race
- (2016) Paul Leger et al. Pharmacogenetics and Genomics
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202
- (2014) Daniel H. Johnson et al. Pharmacogenetics and Genomics
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
- (2012) Emily R. Holzinger et al. Pharmacogenetics and Genomics
- Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort
- (2010) K. R. Robertson et al. NEUROLOGY
- AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT): Rationale, Design, and Baseline Characteristics
- (2008) Marlene Smurzynski et al. HIV CLINICAL TRIALS
- Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
- (2008) C. Wyen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now